Can an antiviral drug stop RSV in vulnerable patients?

NCT ID NCT06817889

Recruiting now Disease control Sponsor: Fred Hutchinson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 07, 2026 · Updated 3 times

Summary

This study tests whether the antiviral drug remdesivir can help treat RSV (a common respiratory virus) in people whose immune systems are weakened by certain cancer treatments or autoimmune therapies. About 60 adults with confirmed RSV will receive remdesivir intravenously. The main goal is to see if it reduces the need for extra oxygen, which would indicate less severe lung infection.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: remdesivir
What this could lead to: If it works, this could provide a treatment option for RSV in people with weakened immune systems, potentially preventing serious lung infections.
What could go wrong: This is an early phase 2 trial with only 60 participants, so results may not apply broadly. Remdesivir may not reduce oxygen needs, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AUTOIMMUNE DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autoimmune disease hematopoietic and lymphoid system neoplasm lymphoma plasma cell myeloma respiratory syncytial virus infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AUTOIMMUNE DISEASE HEMATOPOIETIC AND LYMPHATIC SYSTEM NEOPLASM LYMPHOMA MULTIPLE MYELOMA RESPIRATORY SYNCYTIAL VIRUS INFECTION

Contacts and locations

Locations

City of Hope Comprehensive Cancer Center
RECRUITING

Duarte, California, 91010, United States
Fred Hutch/University of Washington Cancer Consortium
RECRUITING

Seattle, Washington, 98109, United States
MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.